Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH
News Article | May 9, 2017
— Oligodendroglioma market Pipeline Review, H1 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 23 Tables and 11 Figures, 12 Company Profiles, Spread across 130 Pages Report Available at http://www.reportsnreports.com/reports/983992-oligodendroglioma-pipeline-review-h1-2017.html Oligodendroglioma market companies are AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics Inc, F. Hoffmann-La Roche Ltd, Ipsen SA, Millennium Pharmaceuticals Inc, Northwest Biotherapeutics Inc, Novartis AG, Pfizer Inc, Tocagen Inc. Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=983992 Oligodendroglioma (Oncology) report reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 5 and 10 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology). - The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/983992-oligodendroglioma-pipeline-review-h1-2017.html
News Article | May 11, 2017
LONDON, May 11, 2017 /PRNewswire/ -- India Animal Health Care Market: Overview In terms of revenue, the India animal health care market is expected to register a CAGR of 8.0% during the forecast period, 2016–2024. The primary objective of the report is to offer insights on the market dynamics that can influence growth of the India animal health care market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the India animal health care market are presented in the report. Download the full report: https://www.reportbuyer.com/product/4895311/ The India animal health care market is expected to witness significant growth rate in terms of value owing to Increase in consumption of animal protein among human population, rise in epidemics of animal diseases, significant animal population and better technology and growing awareness about animal health management practices contributes to growth of the animal health care market. Moreover, development of novel drugs and vaccines against various animal diseases is creating high potential growth opportunities for players operating in the India animal health care market. Revenue from the animal health care market in India is expected to expand at the relatively higher CAGR due to rising awareness for veterinary care and development of strong distribution channel in India. To understand and assess opportunities in this market, the report offers market forecast on the basis of animal type, therapeutic applications and zones. The report provides analysis of the India animal health care market in terms of market value (US$ Mn). India Animal Health Care Market: Segmentation The India animal health care market is segmented on the basis of animal type: Livestock and Companion. The report begins with the market definition, followed by definitions of the different animal types and different therapeutic applications. The market dynamics section includes TMR's analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the India animal health care market. Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. On the basis of zone, the India animal health care market is segmented into North India, East India, West India, and South India. We have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the India animal health care market. Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked, while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by animal health care market. To understand key segments in terms of their growth and performance in the India animal health care market, Transparency market research has developed a market attractiveness index. The resulting index would help providers identify existing market opportunities. India Animal Health Care Market: Competitive Analysis In the final section of the report, a 'competitive landscape' has been included to provide a dashboard view of key companies operating in the India animal health care market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the India animal health care market and the potential players. However, this section also includes market strategies and SWOT analysis of the main players operational in the India animal health care market. Detailed profiles of players operating in India animal health care market are also included in the scope of the report to evaluate their long- and short-term strategies. Key players included in this report are Merck & Co., Inc. (Intervet India Pvt. Ltd.), Zoetis, Inc., Bayer AG, Elanco, Merial, Boehringer Ingelheim GmbH, Virbac Group, Ceva Santé Animale, Vetoquinol, Intas Pharmaceuticals Ltd., Cipla, Inc. (Cipla Vet), Cargill, Incorporated, Venkys India, Zydus Animal Health, The Himalaya Drug Company, Ayurvet Limited, and Natural Remedies Pvt. Ltd., among others. The India animal health care market has been segmented as follows: By Zone North India East India West India South India By Animal Type Livestock Bovine Species Porcine Species Ovine Species Poultry Species Companion Canine Species Feline Species By Distribution Channel Veterinary Hospitals Veterinary Clinics Pharmacies and Drug Stores Others (Direct Distribution, Pet Shops) By Therapeutic Type Drugs Anti-infective by route of administration Analgesic, Antipyretic, and Anti-inflammatory by route of administration Parasiticides by route of administration Dewormers by route of administration Others by route of administration Vaccines Live Attenuated Vaccine by route of administration Inactivated Vaccine by route of administration Download the full report: https://www.reportbuyer.com/product/4895311/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: firstname.lastname@example.org Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/animal-health-care-market-and-companion-distribution-channel---veterinary-hospitals-veterinary-clinics-pharmacies-drug-stores-direct-distribution-and-pet-shops---india-industry-analysis-size-share-growth-trends-and-fore-300456382.html
News Article | May 12, 2017
HANOVRE, Allemagne, 12 mai 2017 /PRNewswire/-- Cardior Pharmaceuticals a annoncé aujourd'hui la concrétisation de négociations sur un financement de série A se rapportant à 15 millions d'euros et dirigé par LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (avec son nouveau fonds BioMedInvest III) et High-Tech Gründerfonds (HTGF). Cardior est à l'avant-garde de sa technologie exclusive d'ARN promettant de révolutionner la prévision et le traitement de l'insuffisance cardiaque. Les cibles moléculaires sont des ARN non codants liés à l'évolution de l'insuffisance cardiaque et qui contrôlent simultanément la croissance cardiaque et la gestion du calcium par rapport à la contractilité des cardiomyocytes. Le ciblage de certains ARN non codants spécifiques renverse le modelage cardiaque mal adapté pour rétablir la fonction cardiaque normale. « Nous sommes très heureux de piloter ce financement, » a déclaré le Dr Joachim Rothe, associé directeur général de LSP et un des directeurs de Cardior. « Le manque de progrès scientifiques et cliniques dans le domaine cardiovasculaire s'est cruellement fait sentir au cours des dernières 15 années, et Cardior est bien placé pour changer ceci. »
News Article | May 11, 2017
Saniona är ett forsknings- och utvecklingsbolag fokuserat på läkemedel för sjukdomar i centrala nervsystemet, autoimmuna sjukdomar, metaboliska sjukdomar och smärtlindring. Bolaget har en omfattande portfölj av potentiella läkemedelskandidater i preklinisk eller klinisk Fas. Forskningen är inriktad på jonkanaler som utgör en unik proteinklass som möjliggör och kontrollerar passage av laddade joner i cellernas membran. Bolaget samarbetar med Boehringer Ingelheim GmbH. Proximagen Ltd., Productos Medix, S.A de S.V och Luc Therapeutics. Saniona har sitt kontor i Köpenhamn där bolaget har en forskningssite av hög internationell klass. Saniona är noterat på Nasdaq First North Premier och har cirka 5 000 aktieägare. Pareto Securities är Certified Adviser för Saniona. Aktien handlas under tickern SANION. Läs mer på www.saniona.com.
News Article | May 8, 2017
-- American Conference Institute is proud to announce its, which will be held. This conference provides a unique opportunity for in-house practitioners and outside counsel practicing in the biologics space to hear from top industry leaders as they discuss best practices and strategies for successfully navigating this market.With 5 biosimilars now approved, a potential repeal of Obamacare, and a groundbreaking decision expected later this year on the Amgen-Sandoz SCOTUS case, there has never been a more critical time to hear from thought leaders on these important developments. Highlights of this year's event include:- Review of the first 18 Months of Biosimilars and a Look into the Future- Up-to-Date Analysis of Amgen v. Sandoz and Sandoz v. Amgen- Interchangeability and FDA's Recent Guidance, "Considerations in Demonstrating Interchangeability with a Reference Product"- Mastering the Steps and Challenges of the BPCIA- IPRs for Biosimilars- Naming and Suffixes for Biosimilars- Labeling Compliance and FDA's Draft Guidance, "Labeling for Biosimilar Products"- Product Liability Litigation, Pricing, and Reimbursement for Biosimilars- Judicial Perspective on Biosimilar LitigationBrand new this year are our interactive workshop sessions on Navigating Section 101 and 112 Patentability Challenges, and Strategies for Creating an International Biosimilar Portfolio.Our program includes insights from our Biosimilars Advisory Board as well as in-house representatives from companies such as Amgen, Association for Accessible Medicines, BIO, Biogen Inc., Boehringer Ingelheim, Coherus Biosciences Inc., Eisai Inc., Endo Pharmaceuticals Inc., Momenta Pharmaceuticals, National Council for Prescription Drug Programs, Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi.Bruce Leicher, Senior Vice President and General Counsel at Momenta Pharmaceuticals Inc., says "For nearly a decade, the ACI Biosimilars Meeting has provided participants with a sightline into a broad cross section of policy positions, timely updates, and education on key biosimilar strategies. The diversity of views makes this meeting stand out from many others." A member of our esteemed Advisory Board, Bruce, who will be speaking on interchangeability, joins our stellar faculty of Judges, prestigious law-firm leaders, and in-house counsel as they delve into the ins and outs of succeeding in the biologics marketplace.Full information on the forum can be found at http://www.AmericanConference.com/ Biosimilars
News Article | May 9, 2017
XmAb5871: XmAb5871 is a first-in-class monoclonal antibody that targets CD19 with its variable domain, and uses Xencor's XmAb immune inhibitor Fc domain to target FcγRIIb, a receptor that inhibits B-cell function. XmAb5871 is currently in Phase 2 clinical studies for the treatment of IgG4-Related Disease (IgG4-RD) and systemic lupus erythematosus (SLE). Xencor recently completed its subcutaneous (SC) administration Phase 1 study of XmAb5871. Multiple dose SC administration of XmAb5871 was safe and well tolerated at doses of 125 to 375 mg in all 40 subjects administered SC XmAb5871. Treatment emergent adverse events (TEAEs) occurring in subjects receiving any dose of SC XmAb5871 were mild in severity. The only drug-related TEAE occurring in more than two subjects who received any dose of SC XmAb5871 was injection site bruising (three subjects, 8%). No subject receiving SC XmAb5871 discontinued the study due to an adverse event and there were no serious adverse events during the study. Pharmacokinetic and bioavailability data from the study support an every other week dosing schedule. Based on these results, Xencor plans to implement SC administration in newly-initiated clinical trials. At the 3rd International Symposium on IgG4-Related Disease and Fibrosis in February 2017, investigators from Xencor's ongoing Phase 2 study of XmAb5871 in IgG4-RD presented an update on IgG4-RD biomarker development, including flow cytometry methods for measuring circulating B cells, plasmablasts and CD4-positive cytotoxic T lymphocytes. The presentation also included preliminary flow cytometry data for patients enrolled in the ongoing Phase 2 study, which showed a partial reduction in B cells, consistent with previous clinical experience, and a rapid reduction of circulating plasmablasts following treatment with XmAb5871. No significant apoptosis of B cells or CD4 T cells was induced by XmAb5871 therapy. XmAb®7195: XmAb7195 is a first-in-class monoclonal antibody that targets IgE with its variable domain and uses Xencor's XmAb Immune Inhibitor Fc domain to target FcγRIIb, resulting in three distinct mechanisms of action for reducing IgE levels. A subcutaneously administered formulation of XmAb7195 is currently in a Phase 1b study for the treatment of allergic disease. Bispecific Oncology Pipeline: Xencor's initial bispecific antibody programs are tumor-targeted antibodies that contain both a tumor antigen binding domain and a cytotoxic T-cell binding domain (CD3). These bispecific antibodies activate T cells for highly potent and targeted killing of malignant cells. Their XmAb Fc domains confer long circulating half-lives, stability and ease of manufacture. XmAb14045 is currently in a Phase 1 study for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies, and XmAb13676 is currently in a Phase 1 study for the treatment of B-cell malignancies. At the American Association for Cancer Research (AACR) 2017 Annual Meeting in April, Xencor presented preclinical data supporting the development of XmAb18087 for the treatment of SSTR2+ cancers, including neuroendocrine tumors and small cell lung cancer (SCLC). In in vitro and mouse models, XmAb18087 eliminated SSTR2+ tumor cells by stimulating redirected T cell-mediated cytotoxicity, and in cynomolgus monkeys, XmAb18087 stimulated SSTR2-dependent T cell activation, T cell margination and cytokine release. Xencor also presented preclinical data on additional bispecific antibodies deploying its XmAb bispecific and half-life extension technology, highlighting a bispecific antibody targeting PD-1 and an undisclosed co-stimulatory receptor (PD1 x costim) and IL15/IL15Rα heterodimeric Fc-fusions. Partnered XmAb Programs: Nine pharmaceutical companies and the National Institutes of Health are advancing novel drug candidates either discovered at Xencor or that rely on Xencor's proprietary XmAb® technology. Seven such programs are currently undergoing clinical testing. Cash, cash equivalents, and marketable securities totaled $392.7 million as of March 31, 2017, compared to $403.5 million on December 31, 2016. The decrease reflects net spending on operations in the first quarter of 2017. Revenues for the first quarter ended March 31, 2017 were $4.3 million, compared to $7.3 million in the same period of 2016. Decreased revenue for the first quarter of 2017 over revenue for the same period in 2016 is primarily the result of revenue earned from our Amgen collaboration in the first quarter of 2016 compared to milestone revenue received from CSL in the first quarter of 2017. Research and development expenditures for the first quarter ended March 31, 2017 were $15.0 million, compared to $10.0 million for the same period in 2016. Increased research and development spending in the first quarter of 2017 over the same period in 2016 reflects increased spending on our bispecific pipeline of candidates including our first two clinical candidates, XmAb14045 and XmAb13676 and development spending on the next two candidates, XmAb18087 and XmAb20717. General and administrative expenses in the first quarter ended March 31, 2017 were $4.8 million, compared to $4.0 million for the same period in 2016. Increased spending on general and administration in the first quarter of 2017 over the comparable period in 2016 reflects increases in stock based compensation charges in 2017. Non-cash, share based compensation expense for the first quarter ended March 31, 2017 was $3.2 million, compared to $2.0 million for the same period in 2016. Net loss for the first quarter ended March 31, 2017 was $14.6 million, or $(0.31) on a fully diluted per share basis, compared to a net loss of $6.4 million, or ($0.16) on a fully diluted per share basis, for the same period in 2016. The increased loss for the first quarter ended March 31, 2017 compared to 2016 is primarily due to lower revenue of $2.9 million and increased spending of $5.9 million in the first quarter of 2017 compared to the first quarter of 2016. The weighted-average shares outstanding used to compute net loss per share was 46,598,797 for the quarter ended March 31, 2017, compared to 40,626,729 for the quarter ended March 31, 2016. Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations beyond the end of 2020. Xencor expects to end 2017 with approximately $340 million in cash, cash equivalents, and marketable securities. Conference Call and Webcast Xencor will host a conference call today at 4:30 p.m. ET (1:30 p.m. PT) to discuss these first quarter 2017 financial results and provide a corporate update. The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers, and referencing conference ID number: 10271460. A live webcast of the conference call will be available online from the investor relations section of the company website at www.xencor.com. The webcast will be archived on the company website for 30 days. About Xencor, Inc. Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb®14045 in Phase 1 development for acute myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell malignancies; XmAb®18087 in pre-clinical development for the treatment of neuroendocrine tumors; and XmAb®20717 in pre-clinical development for the treatment of multiple cancers. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com. Forward Looking Statements: Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including the quotation from Xencor's President and CEO and any expectations relating to its financial expectations and business, its research and development programs, including XmAb®5871, XmAb®7195, and bispecific programs, including XmAb®14045, XmAb®13676, XmAb®20717 and XmAb®18087, its partnering efforts or its capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. Readers are cautioned not to place undue reliance on such statements and Xencor disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xencor-reports-first-quarter-2017-financial-results-300454645.html
News Article | May 11, 2017
In conjunction with this financing, Cardior appointed Dr. Claudia Ulbrich as Chief Executive Officer. Claudia brings with her two decades of operational management and corporate development experience in pharma and biotech including publicly traded companies. "It is a rare opportunity to develop cutting-edge science in the area of cardiovascular diseases with a high unmet medical need. I am delighted to join Cardior at this exciting development stage of the company and together with its motivated team, quickly put on the map a novel class of drugs and companion diagnostics with the potential to prevent and overcome heart failure," said Dr. Claudia Ulbrich. "The significant funding raised at this stage of development of the company will provide the resources for an ambitious development plan for our lead compound," added Prof Thomas Thum, who is joining the management team as Chief Scientific Officer. With a translational approach and multiple established academic collaborations, Cardior is uniquely positioned to apply innovative first-in-class therapy for myocardial infarction and heart failure patients. Cardior is currently developing non-coding RNA based assets and companion diagnostics. Additionally, Cardior has access to a great variety of discovery programs of undisclosed targets of Prof. Thum's pipeline. While Dechert LLP (Berthold Hummel and Julia Braun, both Corporate, Munich) represented Life Sciences Partners, Boehringer Ingelheim Venture Fund, Bristol-Myers Squibb, BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF) on all legal and tax aspects of the transaction, Cardior Pharmaceuticals and founders was advised by Fieldfisher (Dr. Stefanie Greifeneder, Commercial IP Munich).
Boehringer Ingelheim GmbH | Date: 2012-11-14
The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
Vectura Delivery Devices Ltd and Boehringer Ingelheim GmbH | Date: 2014-09-11
A passive inhaler for delivery of a powder-form inhalation formulation from a blister strip with a plurality of blister pockets is proposed. The inhaler comprises an impaction element onto which the air stream can impact together with entrained inhalation formulation for better deagglomeration. Alternatively, the inhaler comprises an oscillating and/or vibrating device for better de-agglomeration of the inhalation formulation. Alternatively or additionally, the inhaler comprises one or two mixing means for generating swirls, preferably with opposite rotation directions.
Boehringer Ingelheim GmbH | Date: 2013-05-17
The invention relates to a system composed of an inhaler and a capsule, preferably intended for single use. The capsule contains a preferably powdered pharmaceutical preparation which, for inhalation, is expelled from the capsule through at least one hole. The capsule comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. The prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pulling mechanism. Prior to this the hole is closed off by a capsule receptacle or a film. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed. Also shown is an inhaler suitable as a disposable product, which is manufactured from thermoformed parts or from blister film.